XML 43 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 24, 2021
USD ($)
Dec. 01, 2020
USD ($)
item
Jun. 24, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
item
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Collaboration arrangements                
Number of collaboration targets | item           4    
Revenue       $ 463,868 $ 1,535 $ 464,322 $ 1,639  
Accounts receivables       $ 2,705   $ 2,705   $ 6,618
Tax rate enacted in the Netherlands       25.00%   25.00%    
Tax benefit past share issuance cost       $ 2,977   $ 2,977    
CSL Behring collaboration                
Collaboration arrangements                
Revenue       462,400   462,400    
Upfront cash to receive upon the closing of the agreement $ 450,000   $ 450,000          
Other payments received $ 12,400              
Accounts receivables       1,300   1,300   $ 2,100
Regulatory and commercial milestone payments received     $ 1,600,000          
License revenues from related party                
Collaboration arrangements                
Revenue         1,530   1,577  
Collaboration revenues from related party                
Collaboration arrangements                
Revenue         5   62  
Collaboration revenues                
Collaboration arrangements                
Revenue       1,468   $ 1,922    
Collaboration revenues | CSL Behring collaboration                
Collaboration arrangements                
Revenue       $ 400 $ 0   $ 0  
BMS arrangement | Bristol Myers Squibb                
Collaboration arrangements                
Initial research term           4 years    
Number of collaboration targets | item   4            
Collaboration Agreement, Threshold Number Of Collaboration Targets That Can Be Replaced | item   2            
Threshold Number Of New Collaboration Targets In The Field Of Cardiovascular Disease | item   2            
License revenue | Bristol Myers Squibb                
Collaboration arrangements                
Revenue           $ 0    
Bristol Myers Squibb | BMS arrangement                
Collaboration arrangements                
Collaboration Agreement, Threshold Research, Development And Regulatory Milestone Payments Receivable   $ 217,000